Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aakaar Medical TechnologiesNSE:AAKAAR -1.06%20 EBITDA Margin % is 26.23% as of Mar. 2026, which is 111% above its 10-year median of 12.44. GuruFocus rates NSE:AAKAAR with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Aakaar Medical Technologies ranks better than 69% on this metric.
Aakaar Medical Technologies (NSE:AAKAAR) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Aakaar Medical Technologies EBITDA Margin % Related Terms
Aakaar Medical Technologies EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:AAKAAR vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Aakaar Medical Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aakaar Medical Technologies EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aakaar Medical Technologies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Aakaar Medical Technologies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aakaar Medical Technologies (NSE:AAKAAR) has a EBITDA Margin % of 26.23% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aakaar Medical Technologies and its competitors. This is 111% above median its historical median of 12.44. Over the past decade, Aakaar Medical Technologies' EBITDA Margin % has ranged from 10.90 to 16.40. According to the industry distribution chart, Aakaar Medical Technologies ranks #253 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 31%.
Is Aakaar Medical Technologies' EBITDA Margin % too high?
Aakaar Medical Technologies' current EBITDA Margin % of 26.23% is 111% above median its 10-year median of 12.44. Over the past 10 years, this metric has ranged from a low of 10.90 to a high of 16.40. The Medical Devices & Instruments industry median EBITDA Margin % is 7.46. Aakaar Medical Technologies' value of 26.23% is 251.8% above this industry median. Based on the distribution chart, Aakaar Medical Technologies ranks #253 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Aakaar Medical Technologies has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Aakaar Medical Technologies' EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aakaar Medical Technologies ranks #253 out of 816 companies for EBITDA Margin %. This puts Aakaar Medical Technologies in the upper half of its industry. The industry median EBITDA Margin % is 7.46. Aakaar Medical Technologies' value of 26.23% is 251.8% above this benchmark. Historically, Aakaar Medical Technologies' own EBITDA Margin % has ranged from 10.90 to 16.40 over the past decade. While the company's 10-year median is 12.44 vs. the industry median of 7.46, Aakaar Medical Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.46, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aakaar Medical Technologies's current EBITDA Margin % of 26.23% is 251.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aakaar Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aakaar Medical Technologies's current EBITDA Margin % is 26.23%, which is 111% above median its own 10-year median of 12.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aakaar Medical Technologies stock overvalued right now?
Aakaar Medical Technologies (NSE:AAKAAR) has a current EBITDA Margin % of 26.23%. The current EBITDA Margin % is 26.23%, which is 111% above median its 10-year median of 12.44 and 251.8% above the Medical Devices & Instruments industry median of 7.46. Aakaar Medical Technologies' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Aakaar Medical Technologies (NSE:AAKAAR), the current EBITDA Margin % is 26.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aakaar Medical Technologies Ltd is a medical aesthetic company dealing in a wide range of aesthetics & specialized cosmetic products & devices. Its product range includes both Own brands (domestically manufactured products & internationally manufactured devices) and Imported Brands (distribution of imported brands) from countries such as Korea, Spain, Italy, and Austria. It has established a distinctive presence in the medical aesthetic market by exclusively focusing on business-to-business(B2B) channels for product distribution and sales. The company supply its products & devices to dermatologists, plastic surgeons, aesthetic physicians who then sell these products to their end consumers as well as use certain device consumables as part of their treatments.
20GF Score
Get the complete analysis for NSE:AAKAAR
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AAKAAR has been successfully added to your 
